Amicus Therapeutics is an American biopharmaceutical company that is located in Cranbury, New Jersey. Amicus Therapeutics typically focuses on rare and orphan diseases such as Sandhoff disease or Farber disease (Crunchbase). Amicus Therapeutics has poured a ton of research into what is known as ERTs or enzyme replacement therapies. They have contributed a significant amount of research and money into helping to discover cures for various diseases and was even given half a million dollars in 2010 by the Michael J. Fox Foundation to help advance the search of a cure for Parkinson’s disease.
In August of 2017, Amicus Therapeutics announced that there were allowed to submit a new drug application to the United States FDA. Amicus Therapeutics has created a new drug that goes by the name migalastat. This drug is an oral precision medication for Fabry disease and has been diseased to help reduce the morbidity and symptoms of the disease itself. This new drug has been shown to reduce the amount of GL-3 in a human and that lowers the chance of kidney failure, strokes, heart disease and many other symptoms. This is just one of the many projects that Amicus Therapeutics is doing in order to improve each of our lives with new and advanced medication.
Overall, Amicus Therapeutics might be a relatively new company to the world with a foundation in 2002, but this company has provided the world with invaluable information and new research to push the limits of medicine to new frontiers. As Amicus Therapeutics continues to grow and expand we will hopefully see a huge new wave of specialty medications that have been engineered to help with even the most deadly of diseases. Medicine is always changing and Amicus Therapeutics will be one of the companies to help bring a new frontier of health care to millions of people.
More here http://releasefact.com/2017/08/amicus-therapeutics-funds-its-ground-breaking-new-treatment/